MwanzoSGIOF • OTCMKTS
Shionogi & Co Ltd
$ 14.19
Kabla ya soko:
$ 13.79
(2.83%)-0.40
Imefungwa: 12 Feb, 08:00:00 GMT -5 · USD · OTCMKTS · Kanusho
HisaHisa zinazouzwa MarekaniMakao yake makuu ni JP
Bei iliyotangulia
$ 14.19
Bei za mwaka
$ 12.21 - $ 17.83
Thamani ya kampuni katika soko
1.87T JPY
Wastani wa hisa zilizouzwa
28.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
TYO
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(JPY)Des 2024Mabadiliko Tangu Mwaka Uliopita
Mapato
119.63B12.56%
Matumizi ya uendeshaji wa biashara
50.38B-1.47%
Mapato halisi
50.67B38.33%
Kiwango cha faida halisi
42.3622.89%
Mapato kwa kila hisa
EBITDA
58.79B30.07%
Asilimia ya kodi ya mapato
18.66%
Jumla ya mali
Jumla ya dhima
(JPY)Des 2024Mabadiliko Tangu Mwaka Uliopita
Uwekezaji wa pesa taslimu na vipindi vifupi
305.58B7.30%
Jumla ya mali
1.52T11.52%
Jumla ya dhima
153.98B5.81%
Jumla ya hisa
1.36T
hisa zilizosalia
850.69M
Uwiano wa bei na thamani
0.01
Faida inayotokana na mali
8.97%
Faida inayotokana mtaji
9.85%
Mabadiliko halisi ya pesa taslimu
(JPY)Des 2024Mabadiliko Tangu Mwaka Uliopita
Mapato halisi
50.67B38.33%
Pesa kutokana na shughuli
40.80B89.55%
Pesa kutokana na uwekezaji
-17.23B-129.68%
Pesa kutokana na ufadhili
-24.92B50.49%
Mabadiliko halisi ya pesa taslimu
2.17B-93.30%
Mtiririko huru wa pesa
-36.12M-100.05%
Kuhusu
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
17 Mac 1878
Wafanyakazi
4,959
Gundua zaidi
Huenda unavutiwa na
Orodha hii imetokana na maudhui uliyotafuta hivi majuzi, hisa unazofuatilia na shughuli zingine. Pata maelezo zaidi

Data na maelezo yote hutolewa “kama yalivyo” kwa madhumuni ya taarifa binafsi tu, wala hayanuii kuwa ushauri wa kifedha na hayana madhumuni ya kufanya biashara au uwekezaji, kodi, kisheria, uhasibu au ushauri mwingine. Google si mshauri wa uwekezaji wala mshauri wa kifedha na haitoi maoni au mapendekezo yanayohusiana na kampuni zozote zilizojumuishwa kwenye orodha hii au hisa zozote zilizotolewa na kampuni hizo. Tafadhali wasiliana na dalali wako au mwakilishi wa kifedha ili uthibitishe bei kabla ya kufanya biashara yoyote. Pata maelezo zaidi
Watu pia hutafuta
Tafuta
Futa utafutaji
Funga kisanduku cha kutafutia
Programu za Google
Menyu kuu